Clopidogrel does not benefit infants with congenital heart disease

06/19/2013 |

Clopidogrel therapy did not yield better outcomes for babies with cyanotic congenital heart disease and a systemic-to-pulmonary-artery shunt compared with placebo and conventional treatment, a study showed. Rates of death, overall bleeding and severe bleeding were similar for both clopidogel and placebo groups, researchers reported in the New England Journal of Medicine.

View Full Article in:

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN